Intensity modulated radiotherapy for stage III non-small cell lung cancer in the United States: Predictors of use and association with toxicities

Lung Cancer

Volumn 82, Issue 2, 2013, Pages 252-259

  Shirvani, Shervin M ^a   Jiang, Jing ^a   Gomez, Daniel R ^a   Chang, Joe Y ^a   Buchholz, Thomas A ^a   Smith, Benjamin D ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Comparative effectiveness; IMRT; Non small cell lung cancer; Radiation technique; Technology utilization

Indexed keywords

AGED; ARTICLE; BRACHYTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; ESOPHAGUS TOXICITY; FEMALE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MEDICARE; PRIORITY JOURNAL; PROPENSITY SCORE; PROTON THERAPY; TOXICITY; TUMOR VOLUME; UNITED STATES;

COMPARATIVE EFFECTIVENESS; IMRT; NON-SMALL CELL LUNG CANCER; RADIATION TECHNIQUE; TECHNOLOGY UTILIZATION;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, INTENSITY-MODULATED; SEER PROGRAM; TREATMENT OUTCOME; UNITED STATES;

EID: 84887022892     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.08.015     Document Type: Article

References (43)

1. Smith B.D., Smith G.L., Hurria A., Hortobagyi G.N., Buchholz T.A. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 2009, 27:2758-2765.
2. Stinchcombe T.E., Bogart J.A. Novel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancer. Oncologist 2012, 17:682-693.
3. Scarpaci A., Mitra P., Jarrar D., Masters G.A. Multimodality approach to management of stage III non-small cell lung cancer. Surg Oncol Clin N Am 2013, 22:319-328.
4. Albain K.S., Swann R.S., Rusch V.W., Turrisi A.T., Shepherd F.A., Smith C., et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009, 374:379-386.
5. Liu H.H., Wang X., Dong L., Wu Q., Liao Z., Stevens C.W., et al. Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004, 58:1268-1279.
6. Murshed H., Liu H.H., Liao Z., Barker J.L., Wang X., Tucker S.L., et al. Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004, 58:1258-1267.
7. Mayles W.P. Survey of the availability and use of advanced radiotherapy technology in the UK. Clin Oncol (R Coll Radiol) 2010, 22:636-642.
8. Smith B.D., Pan I.W., Shih Y.C., Smith G.L., Harris J.R., Punglia R., et al. Adoption of intensity-modulated radiation therapy for breast cancer in the United States. J Natl Cancer Inst 2011, 103:798-809.
9. Falit B.P., Gross C.P., Roberts K.B. Integrated prostate cancer centers and over-utilization of IMRT: a close look at fee-for-service medicine in radiation oncology. Int J Radiat Oncol Biol Phys 2010, 76:1285-1288.
10. Turner L.M., Howard J.A., Dehghanpour P., Barrett R.D., Rebueno N., Palmer M., et al. Exploring the feasibility of dose escalation positron emission tomography-positive disease with intensity-modulated radiation therapy and the effects on normal tissue structures for thoracic malignancies. Med Dosim 2011, 36:383-388.
11. Sura S., Gupta V., Yorke E., Jackson A., Amols H., Rosenzweig K.E. Intensity-modulated radiation therapy (IMRT) for inoperable non-small cell lung cancer: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience. Radiother Oncol 2008, 87:17-23.
12. Grills I.S., Yan D., Martinez A.A., Vicini F.A., Wong J.W., Kestin L.L. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation. Int J Radiat Oncol Biol Phys 2003, 57:875-890.
13. Yom S.S., Liao Z., Liu H.H., Tucker S.L., Hu C.S., Wei X., et al. Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2007, 68:94-102.
14. Liao Z.X., Komaki R.R., Thames H.D., Liu H.H., Tucker S.L., Mohan R., et al. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys 2010, 76:775-781.
15. Warren J.L., Klabunde C.N., Schrag D., Bach P.B., Riley G.F. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002, 40. IV- IV3 -18.
16. Chen A.B., Neville B.A., Sher D.J., Chen K., Schrag D. Survival outcomes after radiation therapy for stage III non-small-cell lung cancer after adoption of computed tomography-based simulation. J Clin Oncol 2011, 29:2305-2311.
17. Romano P.S., Roos L.L., Jollis J.G. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 1993, 46:1075-1079. discussion 1081-1090.
18. Klabunde C.N., Potosky A.L., Legler J.M., Warren J.L. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000, 53:1258-1267.
19. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
20. Deyo R.A., Cherkin D.C., Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992, 45:613-619.
21. Davidoff A.J., Tang M., Seal B., Edelman M.J. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:2191-2197.
22. Fritz A., Percy C., Jack A., Shanmugarathan K., Sobin L., Parkin D.M., et al. International classification of diseases for oncology 2000, World Health Organization, Geneva, Switzerland. 3rd ed.
23. Guadagnolo B.A., Liao K.P., Elting L., Giordano S., Buchholz T.A., Shih Y.C. Use of radiation therapy in the last 30 days of life among a large population-based cohort of elderly patients in the United States. J Clin Oncol 2013, 31:80-87.
24. Roberts K.B., Soulos P.R., Herrin J., Yu J.B., Long J.B., Dostaler E., et al. The adoption of new adjuvant radiation therapy modalities among medicare beneficiaries with breast cancer: clinical correlates and cost implications. Int J Radiat Oncol Biol Phys 2012.
25. Austin P.C. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 2009, 28:3083-3107.
26. D'Agostino R.B. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998, 17:2265-2281.
27. Schild S.E., Curran W.J. Small cell lung cancer. Clinical radiation oncology 2007, 1827. Elsevier Churchill Livingstone, Philadelphia, PA. L.L. Gunderson, J.E. Tepper (Eds.).
28. Kies M.S., Mira J.G., Crowley J.J., Chen T.T., Pazdur R., Grozea P.N., et al. Multimodal therapy for limited small-cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: a Southwest Oncology Group Study. J Clin Oncol 1987, 5:592-600.
29. Liengswangwong V., Bonner J.A., Shaw E.G., Foote R.L., Frytak S., Eagan R.T., et al. Limited-stage small-cell lung cancer: patterns of intrathoracic recurrence and the implications for thoracic radiotherapy. J Clin Oncol 1994, 12:496-502.
30. Bekelman J.E., Hahn S.M. The body of evidence for advanced technology in radiation oncology. J Natl Cancer Inst 2013, 105:6-7.
31. Nguyen P.L., Gu X., Lipsitz S.R., Choueiri T.K., Choi W.W., Lei Y., et al. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol 2011, 29:1517-1524.
32. Meropol N.J., Schrag D., Smith T.J., Mulvey T.M., Langdon R.M., Blum D., et al. American Society of Clinical O. American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol 2009, 27:3868-3874.
33. Medicare Payment Advisory Commission Report to the Congress: reforming the delivery system; 2008. http://www.medpac.gov/documents/20080916_Sen%20Fin_testimony%20final.pdf.
34. Mitchell J.M., Sunshine J.H. Consequences of physicians' ownership of health care facilities-joint ventures in radiation therapy. N Engl J Med 1992, 327:1497-1501.
35. Smith G.L., Xu Y., Buchholz T.A., Smith B.D., Giordano S.H., Haffty B.G., et al. Brachytherapy for accelerated partial-breast irradiation: a rapidly emerging technology in breast cancer care. J Clin Oncol 2011, 29:157-165.
36. Iglehart J.K. The ACO regulations-some answers, more questions. N Engl J Med 2011, 364:e35.
37. Lieberman S.M., Bertko J.M. Building regulatory and operational flexibility into accountable care organizations and 'shared savings'. Health Aff (Millwood) 2011, 30:23-31.
38. Elnahal S.M., Kerstiens J., Helsper R.S., Zietman A.L., Johnstone P.A. Proton beam therapy and accountable care: the challenges ahead. Int J Radiat Oncol Biol Phys 2012.
39. Wanders R., Steevens J., Botterweck A., Dingemans A.M., Reymen B., Baardwijk A., et al. Treatment with curative intent of stage III non-small cell lung cancer patients of 75 years: a prospective population-based study. Eur J Cancer 2011, 47:2691-2697.
40. Haasbeek C.J., Palma D., Visser O., Lagerwaard F.J., Slotman B., Senan S. Early-stage lung cancer in elderly patients: a population-based study of changes in treatment patterns and survival in the Netherlands. Ann Oncol 2012, 23:2743-2747.
41. Palma D., Visser O., Lagerwaard F.J., Belderbos J., Slotman B., Senan S. Treatment of stage I NSCLC in elderly patients: a population-based matched-pair comparison of stereotactic radiotherapy versus surgery. Radiother Oncol 2011, 101:240-244.
42. Shirvani S.M., Jiang J., Chang J.Y., Welsh J.W., Gomez D.R., Swisher S., et al. Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly. Int J Radiat Oncol Biol Phys 2012, 84:1060-1070.
43. Palma D., Visser O., Lagerwaard F.J., Belderbos J., Slotman B.J., Senan S. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. J Clin Oncol 2010, 28:5153-5159.